Prelude Therapeutics Incorporated (PRLD) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PRLD Hot Sheet
Join SI Premium – FREE
Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q2 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.71 million.
For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- IWBI's Policy Summit: The Conversations Shaping the Next Chapter of Healthy Buildings
- Popular stocks with increasing option volume: INTC SPCX RIOT PLTR CRWV NFLX SMCI SOFI IREN HOOD
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
